MGA (MAX dimerization protein) functions as a dual-specificity transcription factor that acts as both a repressor and activator of gene expression 1. Operating through heterodimerization with MAX, MGA binds E-box sequences and simultaneously blocks corepressor interactions, thereby suppressing MYC-dependent transcriptional activation and cell transformation. MGA regulates both MAX-network and T-box family target genes, with evidence suggesting it modulates the Nme1-OXPHOS axis in certain contexts 2. Clinically, MGA loss-of-function variants are significantly associated with premature ovarian insufficiency (POI), accounting for approximately 2.0% of cases across multiple cohorts 1. Heterozygous MGA mutations were enriched in POI patients while absent in matched controls, and Mga+/- mice exhibited subfertility with reduced follicle numbers, demonstrating MGA's essential role in female reproductive function. In cancer contexts, MGA appears to function as an immune suppressor. Mga knockout in triple-negative breast cancer enhances antitumor immunity and inhibits tumor growth, with low MGA expression correlating with favorable prognosis in patients with active interferon-γ signaling 3. Additionally, MGA mutations occur at elevated frequency in Richter's transformation (36%), where loss of MGA drives CLL progression through altered OXPHOS regulation 2. MGA fusion proteins appear in emerging sarcoma entities, including MGA::NUTM1 fusions 4.